Project aims: To provide a framework that allows structured, meaningful, sustainable and ethical patient engagement throughout three key decision-making points of the development of medicinal products: (i) the research priority setting; (ii) the design of clinical trials and (iii) the early dialogues with regulators and HTA bodies. The work builds upon previous initiatives such the European Patients’ Academy (EUPATI) and Patient Focused Medicine Development (PFMD).
Project leader: European Patients’ Forum (EPF) and the European Federation of Pharmaceutical Industries and Associations (EFPIA)
Main partners: Patient organisations (EPF, EURORDIS, EATG, Alzheimer Europe), Regulators/HTA/Payers (AIFA, HTAi), Academics (CASMI, INSTITUTO ARAGONES DE CIENCIAS DE LA SALUD, Athena Institute, EFGCP, FOUNDATION SAN JOAN DE DEU), SMEs (SYNAPSE, SYNERGIST), EFPIA companies/corporate associations (BAYER, MSD, MERCK, UCB, AMGEN, GRÜNENTHAL, GSK, JANSSEN, LILLY, LUNDBECK, NOVO NORDISK, PFIZER, ROCHE, SERVIER, SANOFI, NOVARTIS, COVANCE, ALEXION, ABPI, VFA)
EATG participation: Project partner, co-leader of WP4 (Co-designed recommendations and resources for patient engagement), involved in all other workpackages as well.
Duration: 30 months, start date 1 March 2018
Main funding source/programme: Innovative Medicines Initiative (IMI)
Budget: Total of 4 498 931 EUR (requested EU contribution), of which EATG budget 381 750 EUR